Clinical and quality of life responses to high-dose chemotherapy plus autologous stem cell transplantation in patients with multiple sclerosis: two case reports.
During the last several years high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) has been established as a therapeutic option for multiple sclerosis (MS) patients. We report on the long-term effects of HDCT + ASCT in two female patients affected by secondary progressive and relapsing-remitting types of MS, respectively. As a result, disease stabilization was achieved in the first case and disease improvement in the second one. Both patients were off immunosuppressive or immunomodulating therapy throughout the post-transplant period. Notably, HDCT + ASCT resulted in an excellent quality of life (QoL) response in both cases. Our findings demonstrate that HDCT + ASCT could be considered as an effective treatment for MS patients. Moreover, QoL measurement seems to be an effective approach to assessment of treatment outcomes at long-term follow-up of patients with MS.
Novik
A A
AA
Russian Cooperative Group for Cellular Therapy, Moscow, Russian Federation.
Ionova
T I
TI
Bisaga
G N
GN
Kishtovich
A V
AV
Fedorenko
D A
DA
Ivanov
R A
RA
Gorodokin
G I
GI
D000328:Adult; D000818:Animals; D000961:Antilymphocyte Serum / Q000494:pharmacology*; D005260:Female; D006736:Horses; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000523:psychology; D010956:Plasmapheresis; D011788:Quality of Life; D012720:Severity of Illness Index; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents